Taclantis^® is a novel formulation of paclitaxel developed with SPARC’s proprietary Nanotecton^TM technology.

Paclitaxel is one of the most widely used cytotoxic agent and is approved for the treatment of Breast cancer, Ovarian cancer, Non Small Cell Lung cancer and Pancreatic cancer.

Taclantis^® is cremophor free and Human Serum Albumin free formulation. Cremophor containing paclitaxel formulations are associated with high incidence of hypersensitivity reactions and are required to be administered slowly and with high dose steroids and anti-histamines as pre-medication. The absence of a biologic protein has advantages such as easier preparation (minimal foaming inside the vial upon reconstitution) and storage (reduced risk for microbial contamination). In addition, it eliminates potential risk of viral/prion transmission from human blood products.

Taclantis^® offers several advantages over available paclitaxel formulations

• Quick and easy "One Step" dilution and infusion preparation
• Shorter infusion time (25 min)
• Significantly higher MTD dose
• No Premedication
• Linear pharmacokinetic profile
• Storage at ambient temperatures

Taclantis^® is currently approved and marketed in India under the trade name Bevetex^® by Sun Pharmaceutical Industries Ltd.

U.S. FDA has accepted for review SPARC’s New Drug Application (NDA) for Taclantis^®. The NDA filing is based on successful demonstration of clinical bioequivalence of Taclantis^® with Abraxane^® and associated clinical safety data.